Abbott Laboratories Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Abbott Laboratories wird ein jährliches Gewinn- und Umsatzwachstum von 11.6% bzw. 6.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 11.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 22% betragen.
Wichtige Informationen
11.6%
Wachstumsrate der Gewinne
11.8%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 17.1% |
| Wachstumsrate der Einnahmen | 6.7% |
| Zukünftige Eigenkapitalrendite | 22.0% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 10 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist
Oct 31
Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Oct 21Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Oct 14Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?
Oct 11Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price
Sep 27Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Sep 11A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Aug 16Abbott Laboratories: Driving Value By Scaling Innovations
Aug 13Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors
Aug 05Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough
Jul 13These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well
Jul 01Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price
Jun 18Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)
Jun 04Abbott Laboratories: Why I Agree With Wall Street On This One
Jun 04Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock
May 18Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now
Mar 21Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger
Mar 19Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
Feb 27Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon
Feb 08The King Is Back: Abbott Laboratories' Path To >11% Annual Returns
Jan 29The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts
Jan 26Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 48,267 | 7,805 | 9,344 | 11,124 | 23 |
| 12/31/2025 | 44,976 | 6,851 | 8,892 | 10,388 | 25 |
| 12/31/2024 | 41,998 | 5,938 | 9,105 | 10,360 | 25 |
| 9/30/2024 | 41,217 | 5,744 | 6,486 | 8,728 | N/A |
| 6/30/2024 | 40,725 | 5,535 | 5,654 | 7,900 | N/A |
| 3/31/2024 | 40,326 | 5,608 | 4,923 | 7,143 | N/A |
| 12/31/2023 | 40,109 | 5,701 | 5,059 | 7,261 | N/A |
| 9/30/2023 | 39,959 | 5,142 | 4,492 | 6,549 | N/A |
| 6/30/2023 | 40,226 | 5,140 | 5,488 | 7,452 | N/A |
| 3/31/2023 | 41,505 | 5,785 | 6,823 | 8,659 | N/A |
| 12/31/2022 | 43,653 | 6,905 | 7,804 | 9,581 | N/A |
| 9/30/2022 | 45,030 | 7,857 | 8,541 | 10,322 | N/A |
| 6/30/2022 | 45,548 | 8,520 | 8,468 | 10,243 | N/A |
| 3/31/2022 | 44,514 | 7,695 | 8,152 | 9,961 | N/A |
| 12/31/2021 | 43,075 | 7,042 | 8,648 | 10,533 | N/A |
| 9/30/2021 | 42,308 | 7,208 | 9,314 | 11,264 | N/A |
| 6/30/2021 | 40,233 | 6,343 | 8,644 | 10,629 | N/A |
| 3/31/2021 | 37,338 | 5,693 | 7,609 | 9,823 | N/A |
| 12/31/2020 | 34,608 | 4,449 | 5,724 | 7,901 | N/A |
| 9/30/2020 | 32,221 | 3,346 | 4,587 | 6,519 | N/A |
| 6/30/2020 | 31,444 | 3,073 | 4,564 | 6,401 | N/A |
| 3/31/2020 | 32,095 | 3,539 | 4,476 | 6,139 | N/A |
| 12/31/2019 | 31,904 | 3,666 | 4,498 | 6,136 | N/A |
| 9/30/2019 | 31,355 | 3,272 | 3,814 | 5,485 | N/A |
| 6/30/2019 | 30,935 | 2,867 | 4,096 | 5,720 | N/A |
| 3/31/2019 | 30,723 | 2,582 | 4,450 | 5,904 | N/A |
| 12/31/2018 | 30,578 | 2,319 | 4,906 | 6,300 | N/A |
| 9/30/2018 | 30,402 | 802 | 4,903 | 6,175 | N/A |
| 6/30/2018 | 29,575 | 812 | N/A | 5,997 | N/A |
| 3/31/2018 | 28,445 | 365 | N/A | 6,104 | N/A |
| 12/31/2017 | 27,390 | 344 | N/A | 5,570 | N/A |
| 9/30/2017 | 25,134 | 1,971 | N/A | 5,100 | N/A |
| 6/30/2017 | 23,607 | 1,055 | N/A | 4,312 | N/A |
| 3/31/2017 | 22,303 | 1,384 | N/A | 3,870 | N/A |
| 12/31/2016 | 20,853 | 1,056 | N/A | 3,203 | N/A |
| 9/30/2016 | 20,708 | 989 | N/A | 2,861 | N/A |
| 6/30/2016 | 20,556 | 1,939 | N/A | 2,839 | N/A |
| 3/31/2016 | 20,393 | 2,124 | N/A | 2,871 | N/A |
| 12/31/2015 | 20,405 | 2,586 | N/A | 2,966 | N/A |
| 9/30/2015 | 20,573 | 2,523 | N/A | 3,376 | N/A |
| 6/30/2015 | 20,502 | 2,365 | N/A | 3,382 | N/A |
| 3/31/2015 | 20,389 | 2,004 | N/A | 3,341 | N/A |
| 12/31/2014 | 20,247 | 1,710 | N/A | 3,675 | N/A |
| 9/30/2014 | 19,905 | 1,560 | N/A | 4,062 | N/A |
| 6/30/2014 | 19,651 | 1,762 | N/A | 3,383 | N/A |
| 3/31/2014 | 19,034 | 1,654 | N/A | 3,200 | N/A |
| 12/31/2013 | 19,657 | 1,970 | N/A | 3,324 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ABTDas prognostizierte Gewinnwachstum (11.6% pro Jahr) liegt über der Sparquote (2.6%).
Ertrag vs. Markt: ABTDie Erträge des Unternehmens (11.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.3% pro Jahr).
Hohe Wachstumserträge: ABTDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: ABTDie Einnahmen des Unternehmens (6.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).
Hohe Wachstumseinnahmen: ABTDie Einnahmen des Unternehmens (6.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ABTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (22%)